Also called propionic aciduria, propionic acidosis (PA) is a rare autosomal recessive metabolic disorder that is a branched-chain organic acidemia. Propionic acidemia is the result of propionyl-CoA carboxylase deficiency (PCC deficiency), which is akin to methylmalonic acidemia arising from methylmalonyl-CoA mutase deficiency. Patients with propionic acidemia are unable to process certain proteins and fats properly, resulting in a buildup of toxic substances such as propionic acid in the blood/water, causing the signs and symptoms of propionic acidemia.
The PCC enzymes include alpha and beta subunits encoded by the PCCA and PCCB genes; mutations in both copies of the PCCA and PCCB genes result in PCC enzyme deficiency. Possible treatments for propionic acidemia may include functional enzyme replacement therapy or mRNA-based PCC therapy.
Encapsuled by LNP, mRNA-3927, a kind of mRNA medicine, comprises genes encoding the PCCA and PCCB for the expression of active PCC enzymes. mRNA-3927 was designed by Moderna to enable the body to restore the missing or dysfunctional PCC enzyme, which leads to propionic acidemia. Moderna's mRNA-3927 has received granted orphan drugs, rare paediatric disease designations, fast track designation from the FDA and orphan drug designation from the EMA for the treatment of propionic acidemia.
A Phase 1/2 study (first-in-human study) is currently underway to evaluate the drug's safety, pharmacologic activity and therapeutic efficacy of mRNA-3927 in patients with genetically confirmed propionic acidemia. In May 2023, Moderna presented that mRNA-3927 was demonstrated generally well-tolerated at the doses interjected from the interim data of the phase 1/2 study.
Yaohai Bio-Pharma Offers One-Stop Solution for RNA
Custom Deliverables
|
Grade
|
Deliverables
|
Specification
|
Applications
|
|
non-GMP
|
Drug Substance, mRNA
|
0.1~10 mg (mRNA)
|
Preclinical research such as cell transfection, Analytical method development, Pre-stability studies, Formulation development
|
|
Drug Product, LNP-mRNA
|
|
GMP, Sterility
|
Drug Substance, mRNA
|
10 mg~70 g
|
Investigational new drug (IND), Clinical trial authorisation (CTA), Clinical trial supply, Biologic license application (BLA), Commercial supply
|
|
Drug Product, LNP-mRNA
|
5000 vials or pre-filled syringes/ cartridges
|
mRNA Therapeutics Pipelines for Propionic Acidemia
|
Code Name
|
Target Protein
|
Indications
|
Manufacturer
|
Latest Stage
|
|
mRNA-3927
|
α and β subunits of PCC enzyme (PCCA and PCCB)
|
Propionic acidemia (PA)
|
Moderna
|
Phase I/II
|
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
